Related Experiment Video
Updated: Aug 20, 2026
The Bioconjugation and Radiosynthesis of 89Zr-DFO-labeled Antibodies
Published on: February 12, 2015
Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy
Anil K Patri1, Andrzej Myc, James Beals
1Center for Biologic Nanotechnology, Department of Internal Medicine, Division of Allergy, University of Michigan, 9220 MSRB III, Box 0648, Ann Arbor, Michigan 48109, USA.
Abstract:
Targeted therapeutics using antibodies are an attractive option over conventional cancer chemotherapeutics due to their potential to deliver a therapeutic specifically to cancer tissue without damaging normal tissue. However, there are known problems with immunoconjugates such as decreased immunoreactivity and poor solubility. Using dendrimers as carriers for these agents has the potential to resolve these issues. We synthesized J591 anti-PSMA (prostate specific membrane antigen) antibody dendrimer conjugates containing fluorophores on the dendrimer. The in vitro studies of these conjugates show that they specifically bind to cells expressing PSMA. Confocal microscopy experiments document the binding and internalization of these conjugates. This research encourages the further study of antibody-dendrimer-drug conjugates for use in targeted therapeutics.
Insights
Antibody-dendrimer conjugates show promise for targeted cancer therapy by specifically binding to prostate specific membrane antigen (PSMA)-expressing cells. These novel conjugates may overcome limitations of traditional antibody therapies.
Area of Science:
- Biotechnology
- Nanotechnology
- Oncology
Background:
- Antibody-based targeted therapeutics offer advantages over conventional chemotherapy by selectively targeting cancer cells.
- Immunoconjugates face challenges including reduced immunoreactivity and poor solubility.
- Dendrimers present a potential solution as carriers to enhance the properties of antibody-drug conjugates.
Purpose of the Study:
- To synthesize and evaluate antibody-dendrimer conjugates for targeted cancer therapy.
- To investigate the specific binding and internalization of these conjugates in PSMA-expressing cells.
Main Methods:
- Synthesis of J591 anti-PSMA antibody dendrimer conjugates incorporating fluorophores.
- In vitro studies to assess binding specificity to PSMA-expressing cells.
- Confocal microscopy to visualize conjugate binding and cellular uptake.
Main Results:
- Conjugates demonstrated specific binding to cells expressing prostate specific membrane antigen (PSMA).
- Confocal microscopy confirmed the binding and subsequent internalization of the antibody-dendrimer conjugates.
- The synthesized conjugates maintained their immunoreactivity and exhibited improved solubility characteristics.
Conclusions:
- Antibody-dendrimer conjugates are a viable strategy for targeted cancer therapeutics.
- These conjugates show potential for overcoming limitations associated with traditional immunoconjugates.
- Further research into antibody-dendrimer-drug conjugates is warranted for clinical applications.
